drugset / Trial / NCT01257802
GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases
Phase 3
Terminated
14 enrolled
Joseph Mccune
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · collabNational Institutes of Health (NIH) · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study it to determine whether the use of a gonadotropin releasing hormone (GnRH)-agonist (depot-leuprolide acetate) during cyclophosphamide (CYC) therapy in women with rheumatic diseases will provide greater ovarian protection than placebo.
Timeline
- Start
- 2011-05
- Primary completion
- 2015-10
- Completion
- 2015-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Leuprolide | Other / unclassified | 3.75 mg | Other |